ACLY and autoimmune polyendocrinopathy: A second series distinguished two subgroups: an unselected APS cohort (aCL-IgM 24.3%, aβ2GPI-IgM 26.4%) and an isolated IgM subset with markedly higher prevalences (aCL-IgM 91.7%, aβ2GPI-IgM 62.5%) [59].